InCube Labs, L.L.C. - 03 Feb 2022 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: 10%+ Owner
Issuer ticker: RANI
Reported as of: 03 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Feb 2022, 20:36:59 UTC
Prior SEC filing: 02 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Josh Seidenfeld, Attorney-in-Fact for Mir Imran, President of InCube Labs, LLC

Key filing fact

InCube Labs, L.L.C. filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 07 Feb 2022.

Key facts

This page summarizes InCube Labs, L.L.C.'s Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Feb 2022, 20:36.

Change

Previous filing in this sequence was filed on 02 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RANI transaction

Class A Common Stock

Other

Transaction value: $0
Shares: +13,923
Change %
Price: $0.000000
Shares after: 13,923
Date: 03 Feb 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Received in kind pro rata distribution from Biologix Partners, LP (3,181 shares of Class A Common Stock) and VH Rani, LP. (10,742 shares of Class A Common Stock), to its limited partners.